Graves Ophthalmopathy

Thyroid Associated Ophthalmopathy

Thyroid Associated Orbitopathy

Simvastatin 40mg

Dpt. of Endocrinology, SUS Malmö

Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS)

Change in 7-point clinical activity score (CAS) after 6 months treatment with simvastatin or no treatment

Number of patients with progression to severe GO in each group (simvastatin, no treatment) during 6 months treatment

Change in Modified clinical activity score after 3 and 6 months treatment with simvastatin or no treatment

Evaluation of conjunctival thickness with optical coherence tomography after 3 and 6 months treatment with simvastatin or no treatment

Quality of life after 6 months treatment with simvastatin or no treatment assessed with the SF36 questionnaire

Quality of life after 6 months treatment with simvastatin or no treatment assessed with the ThyPro questionnaire

Quality of life after 6 months treatment with simvastatin or no treatment assessed with the GO-QoL questionnaire

TRAb after 3 and 6 months treatment with simvastatin or no treatment

TPOAb after 3 and 6 months treatment with simvastatin or no treatment

Lund University

Subjects who will receive atorvastatin 80mg for two weeks

Subject who will receive atorvastatin 10mg

Myocardial Edema

Subject will be given atorvastatin 80mg for two weeks

Atorvastatin 80mg

Subjects will be give atorvastatin 10mg as part of standard therapy in hospital

Atorvastatin 10mg

Effect of 80-mg Atorvastatin on Myocardial Edema

Effect of 80-mg Atorvastatin on Myocardial Edema Following Coronary Artery Bypass Surgery in Relation With Follistatin-Like Protein-1

T2 relaxation time (in ms) difference between control and study group

FSTL1 plasma level difference between control and study group

PKA plasma level difference between control and study group

PKB plasma level difference between control and study group

hs-CRP plasma level difference between control and study group

MDA plasma level difference between control and study group

Rita Zahara

Cardiologist

National Cardiovascular Center Harapan Kita Hospital Indonesia

Chronic Graft-versus-host Disease

Firstline treatment with prednisone and Everolimus

PredEver

Universitätsklinikum Hamburg-Eppendorf

Universitätsklinikum Jena

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Klinikum der Universität Regensburg

Universitätsklinikum Ulm

Deutsche Klinik fuer Diagnostik GmbH

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study -

Patient being alive and having achieved a CR or PR of cGvHD without addition of secondary systemic treatment for cGvHD (see below) and without development of relapse of underlying disease. Addition of any immunosuppressive or immunomodulatory systemic therapy aimed at treating or controlling symptoms of chronic GvHDcGvHD is considered treatment failure. Examples of secondary systemic therapies include (but are not limited to) cyclosporine ACSA, tacrolimus, methotrexate, mycophenolate, rituximab, azathioprine, pentostatine, cyclophosphamid, chloroquine, imatinib, dasatinib, thalidomide, alemtuzumab, etanercept, antithymocyte globulin, infliximab, basiliximab, daclizumab, extracorporeal photopheresis, psoralen with UVA-irradiation (PUVA), pulsed steroid exceeding a dose of 2 mg/kg/day.

To evaluate the time to treatment failure, treatment failure being defined as progression of cGvHD after ≥ 2 weeks in any organ, lack of response (CR/PR) after 12 weeks and/or addition of secondary systemic treatment for cGvHD.

To evaluate the speed of response (time to achievement of CR or PR) of patients treated with prednisone and everolimus for chronic GvHD

To evaluate the relapse rate of underlying malignancies of patients treated with prednisone and everolimus

To assess the side effects of prednisone and everolimus in patients with cGVHD

All adverse events shall be documented and assessed in this study as described in section 9 below. Particular emphasis will be made on the following:
Thrombotic microangiopathy (TMA)
Non-infectious pneumonitis (NIP)
Avascular osteonecrosis

rhabdomyolysis/edema

Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS)

Effect of 80-mg Atorvastatin on Myocardial Edema

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus

Continuous Pressure Monitoring In Lower Leg Fractures

Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation

Il database di erbe medicinali più completo supportato dalla scienza